» Articles » PMID: 35252217

Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance

Overview
Specialty Cell Biology
Date 2022 Mar 7
PMID 35252217
Authors
Affiliations
Soon will be listed here.
Abstract

Immunotherapy has developed rapidly and has gradually become one of the important methods for treatment of gastric cancer (GC). The research on tumor infiltrating immune cells (TIICs) and immune-related genes in the tumor microenvironment (TME) greatly encourages the development of immunotherapy. The devolution algorithm (CIBERSORT) was applied to infer the proportion of 22 TIICs based on gene expression profiles of GC tissues, which were downloaded from TCGA and GEO. TCGA was utilized to analyze the differential expression of immune-related genes, and explore the potential molecular functions of these genes. We have observed the enrichment of multiple TIICs in microenvironment of GC. Some of these cells were closely related to tumor mutational burden (TMB), microsatellite instability (MSI), Fuhrman grade, and TNM staging. Survival analysis showed that the infiltration level of CD8 T cells, activated CD4 memory T cells and M2 macrophages were significantly related to the prognosis of GC patients. The functional enrichment analysis of immune-related genes revealed that these genes were mainly associated with cytokine activation and response. Four significant modules were screened by PPI network and 20 key genes were screened from the modules. The expression levels of CALCR and PTH1R are strikingly related to the expression of immune checkpoint and the prognosis of GC patients. The type and number of TIICs in microenvironment of GC, as well as immune-related genes are closely related to tumor progression, and can be used as important indicators for patient prognosis assessment.

Citing Articles

Recent developments in immunotherapy for gastrointestinal tract cancers.

Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J J Hematol Oncol. 2024; 17(1):65.

PMID: 39123202 PMC: 11316403. DOI: 10.1186/s13045-024-01578-x.


Identification of the Expression of TIE1 and Its Mediated Immunosuppression in Gastric Cancer.

Gong Z, Zheng Q, Li B, Wang H, Chen H, Lin S J Cancer. 2024; 15(10):2994-3009.

PMID: 38706903 PMC: 11064258. DOI: 10.7150/jca.90891.


Comparative transcriptomic and phenotypic analysis of induced pluripotent stem cell hepatocyte-like cells and primary human hepatocytes.

Gandhi N, Wills L, Akers K, Su Y, Niccum P, Murali T Cell Tissue Res. 2024; 396(1):119-139.

PMID: 38369646 DOI: 10.1007/s00441-024-03868-9.


Transcriptomic Establishment of Pig Macrophage Polarization Signatures.

Li J, Yuan T, Zhang A, Yang P, He L, Long K Curr Issues Mol Biol. 2023; 45(3):2338-2350.

PMID: 36975521 PMC: 10047103. DOI: 10.3390/cimb45030151.


N6-methylandenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer.

Huang Y, Zou Y, Tian Y, Yang Z, Hou Z, Li P Front Oncol. 2022; 12:1009881.

PMID: 36523987 PMC: 9745091. DOI: 10.3389/fonc.2022.1009881.


References
1.
Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R . Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017; 127(3):929-941. PMC: 5330718. DOI: 10.1172/JCI89455. View

2.
Oh S, Sohn B, Cheong J, Kim S, Lee J, Park K . Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018; 9(1):1777. PMC: 5934392. DOI: 10.1038/s41467-018-04179-8. View

3.
Pan Q, Wang L, Chai S, Zhang H, Li B . The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. 2020; 11(11):3207-3215. PMC: 7097965. DOI: 10.7150/jca.37285. View

4.
Bense R, Sotiriou C, Piccart-Gebhart M, Haanen J, van Vugt M, de Vries E . Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. J Natl Cancer Inst. 2016; 109(1). PMC: 6284248. DOI: 10.1093/jnci/djw192. View

5.
Goodman A, Sokol E, Frampton G, Lippman S, Kurzrock R . Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019; 7(10):1570-1573. PMC: 6774837. DOI: 10.1158/2326-6066.CIR-19-0149. View